CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED) - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2021			97,574,171
Beginning balance at Dec. 31, 2021	$ 40,799	$ (1,962)	$ 10	$ 77,632	$ (36,843)	$ (1,962)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			275,435
Stock options exercised	60			60
Vesting of restricted stock units (in shares)			378,425
Repurchases of restricted stock for payroll tax withholding (in shares)			(102,019)
Repurchases of restricted stock for payroll tax withholding	(195)			(195)
Stock-based compensation expense	1,089			1,089
Net loss	(6,039)				(6,039)
Ending balance (in shares) at Mar. 31, 2022			98,126,012
Ending balance at Mar. 31, 2022	$ 33,752		$ 10	78,586	(44,844)
Beginning balance (in shares) at Dec. 31, 2022	98,585,563		98,585,563
Beginning balance at Dec. 31, 2022	$ 7,128		$ 10	83,794	(76,676)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of warrants in connection with Credit Agreement amendment	4,060			4,060
Vesting of restricted stock units (in shares)			1,251,503
Repurchases of restricted stock for payroll tax withholding (in shares)			(275,918)
Repurchases of restricted stock for payroll tax withholding	(163)			(163)
Stock-based compensation expense	2,090			2,090
Net loss	$ (9,114)				(9,114)
Ending balance (in shares) at Mar. 31, 2023	99,561,148		99,561,148
Ending balance at Mar. 31, 2023	$ 4,001		$ 10	$ 89,781	$ (85,790)